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ABSTRACT
Background Human cancers are extraordinarily 
heterogeneous in terms of tumor antigen expression, 
immune infiltration and composition. A common feature, 
however, is the host′s inability to mount potent immune 
responses that prevent tumor growth effectively. Often, 
naturally primed CD8+ T cells against solid tumors lack 
adequate stimulation and efficient tumor tissue penetration 
due to an immune hostile tumor microenvironment.
Methods To address these shortcomings, we cloned 
tumor- associated antigens (TAA) and the immune- 
stimulatory ligand 4- 1BBL into the genome of modified 
vaccinia Ankara (MVA) for intratumoral virotherapy.
Results Local treatment with MVA- TAA-4- 1BBL resulted 
in control of established tumors. Intratumoral injection of 
MVA localized mainly to the tumor with minimal leakage 
to the tumor- draining lymph node. In situ infection by 
MVA- TAA-4- 1BBL triggered profound changes in the tumor 
microenvironment, including the induction of multiple 
proinflammatory molecules and immunogenic cell death. 
These changes led to the reactivation and expansion of 
antigen- experienced, tumor- specific cytotoxic CD8+ T cells 
that were essential for the therapeutic antitumor effect. 
Strikingly, we report the induction of a systemic antitumor 
immune response including tumor antigen spread by 
local MVA- TAA-4- 1BBL treatment which controlled tumor 
growth at distant, untreated lesions and protected against 
local and systemic tumor rechallenge. In all cases, 4- 1BBL 
adjuvanted MVA was superior to MVA.
Conclusion Intratumoral 4- 1BBL- armed MVA 
immunotherapy induced a profound reactivation and 
expansion of potent tumor- specific CD8+ T cells as well 
as favorable proinflammatory changes in the tumor 
microenvironment, leading to elimination of tumors and 
protective immunological memory.
INTRODUCTION
The lack of potent immune responses against 
solid tumors due to the poor capacity of 
immune cells to infiltrate or perform effector 
functions in the hostile tumor microenviron-
ment (TME) is a major challenge for cancer 
immunotherapy.1 The concept of reprogram-
ming the immunosuppressive TME into an 
inflammatory one by tumor- directed therapy 
has attracted much attention in recent years.2 
The aim is to activate immune cells that have 
already homed to the tumor tissue and local 
lymph nodes or to recruit new immune cells 
to the TME, while minimizing irrelevant acti-
vation of the rest of the immune system.3 
To achieve so, several strategies are being 
explored in preclinical models as well as in 
the clinic, either employing the local release 
and activation of biochemical signals derived 
from pathogen recognition and unpro-
grammed cell destruction or local adminis-
tration of immunostimulatory monoclonal 
antibodies and cytokines.3
Local oncolytic virotherapy relies on the 
concept of tumor- targeted therapy through 
specific infection and destruction of tumor 
cells and modulation of the TME. The 
recent Food and Drug Administration (FDA) 
approval of the first- in- class oncolytic agent 
IMLYGIC, a modified herpes simplex virus 
1 encoding human granulocyte- macrophage 
colony- stimulating factor (GM- CSF), for stage 
III melanoma patients,4 emphasized the great 
potential of oncolytic viruses (OVs). There is 
a wide spectrum of viral families that have 
been investigated for their oncolytic effects, 
including herpesvirus, poxvirus and adeno-
virus, among others.5
While historically tumor cell- specific repli-
cation and direct killing activity of OVs were 
considered the primary mode of action, 
initiation or augmentation of a host anti-
tumor immune response is now known 
to be essential for oncolytic virotherapy.6 
Hence, local virotherapy can be regarded as 
an in situ vaccine that leads to the release 
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of damage- associated or pathogen- associated molecular 
patterns and immunogenic cell death accompanied by 
tumor antigen release which ultimately results in the 
initiation of innate and adaptive antitumor immune 
responses.7
Modified vaccinia Ankara (MVA)- BN is a highly atten-
uated vaccinia strain approved by the FDA (JYNNEOS) 
as a non- replicating vaccine against smallpox and 
monkeypox.8 In addition, a recombinant MVA- BN vaccine 
vector has recently been approved by the European Medi-
cines Agency (EMA) as part of an Ebola vaccine and others 
are employed in clinical trials against various infectious 
agents as well as in immuno- oncology.9 10 MVA is a potent 
inducer of type I interferons (IFN)11 12 and elicits robust 
humoral and cellular immune responses against vector- 
encoded heterologous antigens.13 14 Importantly, MVA 
cannot replicate in human cells as its replication ability 
is largely restricted to embryonic avian cells.15 Thus, the 
excellent safety profile and immune- stimulatory proper-
ties of MVA make it a prime candidate for therapeutic 
interventions.16
MVA can accommodate large transgene inserts facili-
tating the incorporation of heterologous antigens and 
immune- stimulatory molecules to elicit antigen- specific 
T cell responses and enhance certain immune- activating 
pathways. CD40L- adjuvanted MVA drastically augmented 
innate and adaptive immune responses upon intrave-
nous injection.17 18 Furthermore, OVs genetically altered 
with co- stimulatory molecules or inflammatory cytokines 
increased therapeutic efficacy after intratumoral (IT) 
therapy.5 Hence, IT treatment with MVA encoding a 
tumor- associated antigen (TAA) together with a costim-
ulatory molecule might enhance antitumor immune 
responses in the TME.
The tumor necrosis factor receptor (TNF)- family 
member 4- 1BB or CD137 is defined as a bona fide costim-
ulatory molecule in T cells. 4- 1BB is transiently induced on 
T cell receptor (TCR) stimulation and subsequent engage-
ment of this costimulatory receptor leads to elevated levels 
of cytokine secretion as well as the upregulation of the 
antiapoptotic molecules Bcl-2 and Bcl- xL. This results in 
increased proliferation and protection against activation- 
induced T cell death which is also critical for forming immu-
nological memory.19 4- 1BB expression in tumor- infiltrating 
T cells (TIL),20 coupled with its capacity to promote 
survival, expansion, and enhanced effector function of 
activated T cells, has made it an alluring target for cancer 
immunotherapy. Indeed, stimulation of the costimulatory 
pathway 4- 1BB/4- 1BBL is beneficial in many therapeutic 
cancer settings including mono- or combination- therapies 
with agonistic 4- 1BB antibodies or 4- 1BBL- expressing viral 
vectors.21 However, systemic agonistic 4- 1BB antibodies 
were hampered in clinical trials by severe liver toxicity.22 
Therefore, the next generation of 4- 1BB targeting strat-
egies attempts to leverage the on- target liver toxicity by 
increasing tumor- specific targeting.23 24
In this study, we combined the immune- stimulatory 
properties of TAA- encoding MVA with the exquisite T 
cell- enhancing potential of 4- 1BBL and evaluated ther-
apeutic efficacy against solid tumors. We found that IT 
injection of MVA- TAA-4- 1BBL exerted strong objective 
therapeutic responses in various unrelated tumor models. 
The therapy was due to strongly reactivated tumor- specific 
CD8+ T cells and the favorable induction of multiple 
proinflammatory chemokines and cytokines in the TME. 
Furthermore, IT MVA- TAA-4- 1BBL injection induced 
systemic antitumor immune responses inhibiting growth 
of tumor deposits at distant sites. Importantly, IT MVA- 
TAA-4- 1BBL triggered the generation of a diversified 
tumor- specific memory response that protected against 
local and metastatic recurrence.
MATERIALS AND METHODS
Mice and tumor cell lines
Female C57BL/6J (H-2b) and Balb/cJ (H-2d) mice aged 
6–8 weeks were purchased from Janvier Labs. C57BL/6- Tg 
(TcraTcrb) 1100Mjb/J (OT- I) and B6.SJL- Ptprca Pepcb/
BoyJ (CD45.1) mice were obtained from the University of 
Zurich and bred to obtain CD45.1+ OT- I mice. All mice 
were handled, fed, bred and maintained either in the 
animal facilities at Bavarian Nordic (BN), at the Univer-
sity of Zurich or at the University of Navarra according to 
institutional guidelines.
The B16.OVA melanoma cell line was a kind gift of 
Roman Spörri (ETH Zurich). B16.F10 (ATCC CRL-6475) 
and CT26 wild type (CT26.WT) (ATCC CRL-2638) 
cell lines were purchased from American Type Culture 
Collection (ATCC). Tumor cells were cultured in DMEM 
Glutamax medium supplemented with 10% FCS, 1% 
NEAA, 1% Sodium Pyruvate and 1% Penicillin/Strep-
tomycin (all reagents from Gibco) in an incubator at 
37°C 5% CO2. All tumor cell lines used in experiments 
conducted at BN were regularly tested negative for Myco-
plasma by PCR (results available on request).
Immunizations
IT injections were given into the solid tumor mass with 
a total volume of 50 µL containing the respective MVA 
recombinants. Repetitive IT injections were performed at 
days 0, 5 and 8 after tumor grouping, and indicated in 
the graphs by vertical dotted lines. When indicated, blood 
was collected 3 days after last IT immunization for periph-
eral blood immune cell phenotyping.
Statistical analysis
Statistical analyses were performed as described in the 
figure legends using GraphPad Prism V.7.02 for Windows 
(GraphPad Software, La Jolla, California, USA). For 
immunological data, results are presented as mean and 
SE of the mean. Either analysis of variance with multiple 
comparisons test or one- tailed unpaired Student′s t- tests 
were used to determine statistical significance between 
treatment groups. For tumor- bearing mice survival after 
treatment, log- rank tests were performed to determine 
statistical significance between treatment groups.
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RESULTS
4-1BBL potentiates IT MVA immunotherapy
IT application of poxviruses has been shown to effectively 
induce antitumor responses in various tumor models.25 26 
However, most of these studies have been conducted with 
replicating viruses. Here, we tested whether local treat-
ment of established tumors using the non- replicating 
poxvirus MVA encoding a TAA and the costimulatory 
molecule 4- 1BBL would convey potent antitumor effects.
IT injections of MVA encoding the TAA ovalbumin 
(herein referred to as MVA- OVA) controlled tumor 
growth and prolonged survival of mice bearing estab-
lished B16.OVA melanomas (figure 1A,B). Notably, IT 
administration of MVA- OVA-4- 1BBL increased tumor 
rejection to 50% of B16.OVA tumor- bearing mice 
(figure 1B). Analysis of peripheral blood lymphocytes 
(PBLs) after the last IT injection revealed that systemic 
expansion of TAA- specific CD8+ T cells triggered by local 
MVA- OVA treatment was increased by MVA- OVA-4- 1BBL 
IT administration (online supplemental figure 1, online 
supplemental file 1).
Next, we evaluated other independent, established 
tumor models. IT administration of MVA encoding the 
endogenous retroviral antigen Gp7027 (herein referred 
to as MVA- Gp70) resulted in antitumor effects in B16.
F10 melanomas (figure 1C,D). Interestingly, IT MVA- 
Gp70-4- 1BBL markedly prolonged tumor growth control 
and significantly improved mouse survival (figure 1C,D). 
Similar results were observed in CT26.WT tumor- bearing 
mice after IT immunization with either MVA- Gp70 or 
MVA- Gp70-4- 1BBL (figure 1E,F). Local administration 
of MVA- Gp70-4- 1BBL resulted in over 80% rejection of 
CT26.WT tumors. Restimulation of PBLs with Gp70- 
derived peptides revealed a robust induction of IFNγ by 
p15E604-611 (H- 2K
b- restricted Gp70 peptide)- and AH16-14 
(H- 2Kd- restricted Gp70 peptide)- specific CD8+ T cells on 
MVA- Gp70-4- 1BBL IT regime in B16.F10 and CT26.WT 
tumor- bearing mice, respectively (online supplemental 
Figure 1 Therapeutic efficacy of intratumoral (IT) administration of MVA- TAA-4- 1BBL in unrelated tumor models is 
independent of the choice of antigen. C57BL/6 (A–D) or Balb/c mice (E, F) received either 5×105 B16.OVA (A, B), 5×105 B16.F10 
(C, D) or 5×105 CT26.WT (E, F) cells subcutaneously (SC) in the flank. 7–14 days later, when tumor volumes were above 60 mm3, 
mice were immunized intratumorally (IT) either with phosphate buffered saline (PBS) or with the indicated MVA constructs. IT 
immunization was repeated on days 4 or 5 and 8 after the first immunization (dotted lines). (A) Tumor size follow- up (n=5 mice/
group) and (B) overall survival (n=20 mice/group) of B16.OVA bearing mice injected either with PBS, 2×108 TCID50 MVA- OVA or 
2×108 TCID50 MVA- OVA-4- 1BBL; (C) tumor size follow- up (n=5 mice/group) and (D) overall survival (n=15 mice/group) of B16.
F10 bearing mice injected either with PBS, 5×107 TCID50 MVA- Gp70 or 5×10
7 TCID50 MVA- Gp70-4- 1BBL; (E) tumor size follow- 
up (n=5 mice/group) and (F) overall survival (n=10 mice/group) of CT26.WT bearing mice injected either with PBS, 5×107 TCID50 
MVA- Gp70 or 5×107 TCID50 MVA- Gp70-4- 1BBL. (A, C, E) Data are representative of at least two independent experiments. 
(B, D, F) Represent overall survival of at least two merged independent experiments. Log- rank test on mouse survival was 
performed for figures B, D, F. *P<0.05; **p<0.01; ****p<0.0001. IT, intratumoral; MVA, modified vaccinia Ankara; OVA, ovalbumin; 
PBS, phosphate buffered saline; SC, subcutaneous.
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figures S1B and S1C), respectively). Of note, over 70% 
of C57BL/6 mice that were cured on MVA- OVA-4- 1BBL 
or MVA- Gp70-4- 1BBL IT treatment developed vitiligo 
(online supplemental figure 1 D and E).
CD8+ T cell induction by 4-1BBL adjuvanted MVA dictates 
antitumor immune responses
We have observed a relationship between tumor growth 
control and the expansion of TAA- specific CD8+ T cells 
in the blood upon IT MVA- TAA-4- 1BBL administration. 
Hence, we first interrogated whether 4- 1BB ligation affects 
the quality of antigen- specific CD8+ T cell activation in 
vitro. Coculture of OT- I CD8+ T cells and MVA- OVA-4- 
1BBL infected B16.F10 cells led to significantly increased 
frequencies of Granzyme B- and IFNγ−expressing OT-1 
CD8+ T cells compared with MVA- OVA -infected coun-
terparts (online supplemental figures S2A and S2B). 
Furthermore, substantial production of IFNγ, TNFα and 
GM- CSF was detected in the supernatant of cocultures of 
OT- I CD8+ T cells and MVA- OVA-4- 1BBL -infected B16.
F10 cells (online supplemental figure S2C).
Next, we analyzed T cell activation and dynamics directly 
in the TME and the tumor- draining lymph node (TdLN) 
after IT MVA injection. An increase in the number of 
CD8+ T cells in the TdLN was observed already 3 days after 
IT immunization with MVA vectors and further expanded 
by day 7 (figure 2B). The number of CD8+ T cells infil-
trating the TME peaked by day 7 after IT MVA injection 
(figure 2A). Importantly, in both organs, MVA- OVA-4- 
1BBL significantly elevated the number of infiltrating 
CD8+ T cells as compared with MVA- OVA (figure 2A,B). A 
similar expansion kinetics was detected for CD4+ T cells, 
however these cells were not further enhanced by 4- 1BB 
ligation (online supplemental figures S3A and S3B).
Analysis of antitumor responses revealed a peak of 
expansion of OVA- specific CD8+ T cells in the TdLN 
3 days after MVA IT injection. By day 7, OVA- specific 
CD8+ T cells dropped in the TdLN but were significantly 
expanded in the TME (figure 2C,D). By contrast, MVA- 
specific CD8+ T cells increased in the tumor and the 
TdLN on day 7 (figure 2E,F). Notably, numbers of OVA- 
as well as MVA- specific CD8+ T cells were significantly 
elevated by 4- 1BBL adjuvanted MVA (figure 2C–2F). 
Lag3 and PD-1 are highly expressed on functionally 
impaired TILs, thereby contributing to tumor- mediated 
immune suppression.28 Indeed, OVA- specific CD8+ TILs 
in untreated tumors expressed high levels of both Lag3 
and PD-1. Expression of both surface markers by OVA- 
specific CD8+ TILs was decreased after treatment (online 
supplemental figure S3C and SD). In addition, IT MVA 
injection led to a significant reduction of CD4+ regula-
tory T cells (Treg) in the TME (online supplemental figure 
S3E). This resulted in an elevated OVA- specific CD8+ T 
cell (Teff) to Treg ratio (online supplemental figure S3F).
Driven by our findings, we investigated the contribu-
tion of CD8+ T cells to MVA- Gp70-4- 1BBL- mediated 
antitumor effects. Repetitive IT injections using MVA- 
Gp70-4- 1BBL led to tumor growth control and prolonged 
survival of B16.F10 tumor- bearing mice as compared with 
PBS (figure 2G,H). Antibody depletion of CD8+ T cells 
resulted in complete loss of therapeutic efficacy of IT 
MVA- Gp70-4- 1BBL injection. In addition, depletion of 
both CD4+ T cells and natural killer (NK) cells increased 
MVA- Gp70-4- 1BBL- mediated antitumor effects (online 
supplemental figure S4). Together, these results deter-
mine a central role for CD8+ T cells in the therapeutic 
responses to MVA adjuvanted with 4- 1BBL.
IT injected MVA localizes to the tumor and induces changes in 
the tumor microenvironment
Having established that T cells rapidly expanded in 
the TdLN after IT MVA injection raised the ques-
tion whether replication- deficient MVA would reside 
exclusively at the site of injection or transit to other 
organs. Six hours after IT injection of MVA encoding 
luciferase (herein referred to as MVA- Luc), high 
bioluminescence was detected within B16.F10 tumors 
and decreased upon time (figure 3A,B). Ex vivo anal-
ysis of tumor, TdLN and non- draining lymph node 
(NdLN) 6 hours after IT injection revealed that biolu-
minescence was not only detected in the tumor, but 
also in TdLN (figure 3C). We confirmed these results 
using a MVA vector expressing a soluble form of 
the human growth factor FMS- like tyrosine kinase 3 
ligand (huFlt3L) (online supplemental figure S5A). 
Furthermore, we determined the presence of MVA- 
derived genomic DNA (gDNA) in tumor, TdLN, 
NdLN and peripheral organs 6 hour after IT injection. 
Similarly, MVA gDNA was detected at high amounts 
in B16.F10 tumors with minimal appearance in the 
TdLN (figure 3D). Of note, minute amounts of MVA 
gDNA were detected in lung, liver, spleen and blood 
(figure 3E). The use of certain 4- 1BB agonists has 
been associated with severe liver damage in preclin-
ical models29 30 and clinical trials.22 IT administration 
of MVA- Gp70-4- 1BBL neither resulted in elevated 
alanine aminotransferase (ALT) levels (figure 3F) nor 
in increased liver weight, hepatic CD8+ T cell infil-
tration, proliferation or cytotoxicity (online supple-
mental figure S5B- F). All these features were observed 
when using IV injection of the anti-4- 1BB clone 3H3 
as positive control.
We demonstrated that after IT application MVA 
infection is primarily constrained to the tumor and 
thus virus- induced antitumor immune responses 
most likely originated in the tumor. Therefore, we 
hypothesized that IT injection of MVA- TAA-4- 1BBL 
might induce changes in the TME. IT injection of 
B16.OVA tumors either with MVA or MVA- OVA led 
to an upregulation of the proinflammatory molecules 
IFNα, TNFα, CXCL10 and CCL2 compared with PBS. 
This effect was significantly increased by MVA- OVA-
4- 1BBL (figure 3G; online supplemental figure S6A). 
Interestingly, cytokines such as IFNγ and GM- CSF 
were almost exclusively induced by 4- 1BBL adjuvanted 
MVA (figure 3G).
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Replicating viruses induce death of infected tumor 
cells and immune cells.5 Infection with MVA, MVA- TAA 
or MVA- TAA-4- 1BBL enhanced B16.OVA and CT26.
WT tumor cell death in vitro (online supplemental 
figure S6B). Macrophages which have been shown to 
be preferentially infected by MVA31 were effectively 
killed, whereby this effect was significantly increased 
by 4- 1BBL adjuvant (online supplemental figure 
Figure 2 CD8+ T cell expansion and dependency on IT MVA- OVA-4- 1BBL. C57BL/6 mice received 5×105 B16.OVA cells 
subcutaneously in the flank. Ten days later when tumor volumes were around 80 mm3, mice were grouped and IT injected with 
either PBS, 2×108 TCID50 MVA- OVA or MVA- OVA-4- 1BBL. 1, 3 and 7 days after immunization, mice were sacrificed for further 
analysis (n=5–11 mice/group). (A) Number of CD8+ T cells per Mg tumor; (B) number of CD8+ T cells per tumor- draining lymph 
node (TdLN); (C) number of OVA257-264 –specific CD8
+ T cells per Mg tumor; (D) number of OVA257-264 –specific CD8
+ T cells per 
TdLN; (E) Number of B820-27 –specific CD8
+ T cells per Mg tumor; (F) number of B820-27 –specific CD8
+ T cells per TdLN; (G, 
H) When B16.F10 tumor volumes were above 60 mm3, mice received PBS or were immunized IT with 5×107 TCID50 of MVA- 
Gp70-4- 1BBL. IT immunization was repeated on day 5 and 8 after the first immunization (dotted lines). Mice received 200 µg of 
either IgG2b or anti- CD8 antibody intraperitoneally (IP) at day −2, 2, 6 and 10 after immunization; (G) tumor size follow- up (n=8 
mice/group) and (H) overall survival (n=8 mice/group). Data in A–F expressed as mean±SEM A–F two- way ANOVA comparing 
cell numbers in analyzed organs on treatment. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. Log- rank test on mouse survival 
was performed for (H). **P<0.01; ***p<0.001. ANOVA, analysis of variance; IP, intraperitoneally; IT, intratumoral; MVA, modified 
vaccinia Ankara; n.s., non- significant; OVA, ovalbumin; PBS, phosphate buffered saline; SC, subcutaneous; SEM, SE of the 
mean.
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S6B). Cell death results in the release of intracel-
lular proteins such as High Molecular Group Box 1 
(HMGB1) that are sensed by innate immune cells and 
contribute to the initiation of immune responses.32 
A significant increase of HMGB1 was detected after 
MVA infection of tumor cells or macrophages irre-
spective of 4- 1BBL (online supplemental figure S6C).
Our results suggest that local injection of MVA resulted 
in IT expression of MVA encoded genes, leading to the 
induction of inflammation, cell death of infected cells 
and release of immunogenic mediators in the TME.
Figure 3 MVA localization and induction of inflammation on IT MVA injection. (A–C) C57BL/6 mice received 5×105 B16.F10 
cells SC. (A–C) Five days after tumor inoculation, mice were grouped (n=3 mice/group) and administered IT either with PBS 
or with 5×107 TCID50 MVA- Luc. (A, B) 6, 24 and 48 hours after IT injection, mice received 150 µg luciferin IP. 10 min later, mice 
under inhaled anesthesia were assessed for 2 min for bioluminescence using an in vivo imaging system. (A) Representative 
dorsal images of assayed mice 6 hour after it injection; (B) Photons per second per diameter (ph/s/cm²/sr) in gated regions of 
interest. Data graph represents two independent experiments (n=3 mice per group) (C) 6 hour after IT injection, mice received 
150 µg Luciferin intraperitoneally and were immediately sacrificed to harvest tumor, TdLN and NdLN. Then bioluminescence 
of the individual organs was assessed (ph/s/cm²/sr). Presented data are representative of two independent experiments. (D, 
E) C57BL/6 mice received 5×105 B16.OVA cells SC. When tumors reached 60 mm3, mice were grouped (n=4–5 mice/group) 
and administered IT either with PBS or with 2×108 TCID50 MVA. Six hours after IT injection tumor, TdLN, NdLN (D) and blood, 
spleen, lung and liver (E) were snap- frozen and viral DNA was extracted from tissue lysates. Gene Copies (gcs) of the MVA 
gene MVA082L in the different organs is shown. (F) Assessment of liver damage. Schematic representation. Briefly, when B16.
F10 tumor volumes were above 60 mm3, mice were injected it with 2×108 TCID50 of MVA- Gp70-4- 1BBL on days 0, 5 and 8. 
As positive control, naïve C57BL/6 mice received 500 µg of anti-4- 1BB antibody (clone 3H3) IV twice per week (n=5–8 mice). 
Mice were bled at the indicated time points and ALT serum levels were determined. (G) C57BL/6 mice received 5×105 B16.OVA 
cells. When tumors reached 60 mm3, mice were grouped (n=10 mice/group) and administered IT either with PBS or with 2×108 
TCID50 MVA, MVA- OVA or MVA- OVA-4- 1BBL. Six hours after IT injection, tumors were extracted and tumor lysates processed. 
Concentration (pg/mL) of indicated cytokines/chemokines in tumor lysates is shown. Data in B–G expressed as mean±SEM. 
(B–F) Two- way ANOVA was performed. *P<0.05; ***p<0.005; ****p<0.0001. (G) One- way ANOVA was performed. *P<0.05; 
**p<0.01; ****p<0.0001. ALT, alanine aminotransferase; ANOVA, analysis of variance; GC, gene copies; IP, intraperitoneally; IT, 
intratumoral; IV, intravenous; Luc, luciferase; MVA, modified vaccinia Ankara; NdLN, non- draining lymph node; OVA, ovalbumin; 
PBS, phosphate buffered saline; SC, subcutaneous; SEM, SE of the mean; TdLN, tumor- draining lymph node.
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Local MVA immunotherapy controls tumor growth of distant 
untreated lesions
As local treatment with MVA- TAA-4- 1BBL not only 
induced robust tumor- specific T cell responses in 
the TME but also in the blood, we next assessed the 
systemic antitumor potential of IT MVA immuno-
therapy on distant tumor deposits. CT26.WT tumor 
cells were implanted subcutaneously to the right and 
the left flank of Balb/c mice (figure 4A). IT injection 
of MVA- Gp70 delayed tumor growth as compared 
with PBS (figure 4B,C). IT MVA- Gp70-4- 1BBL injec-
tion resulted in clearance of the treated tumor in 
6/10 CT26. WT tumor- bearing mice (figure 4D). 
Importantly, local administration of both MVA- Gp70 
and MVA- Gp70-4- 1BBL led to tumor growth delay 
and, in some cases, complete tumor clearance of the 
untreated tumor lesions (figure 4C,D). These data 
demonstrate the effective induction of antitumor 
immune responses against distant, untreated tumor 
lesions by IT MVA immunotherapy.
IT MVA-TAA-4-1BBL treatment protects from local tumor 
rechallenge and induces epitope spreading
One of the main goals of cancer vaccines is to achieve 
long- term protective immunological memory to prevent 
tumor recurrence. Therefore, we first assessed whether 
IT MVA- TAA-4- 1BBL- induced antitumor responses 
generate immunological memory that protects against 
local tumor rechallenge (figure 5A). Naïve mice used 
as controls rapidly grew tumors in 100% of mice. Mice 
that were previously cured after IT MVA- OVA treatment 
had a high prevalence for tumor regrowth of 60% on 
rechallenge. In contrast, about 80% of mice (9/11) that 
previously received IT MVA- OVA-4- 1BBL were resistant to 
secondary tumor growth (figure 5B). Similar results were 
obtained in mice that were cured after MVA- Gp70-4- 1BBL 
treatment and local rechallenge with B16.F10 cells. About 
55% of pretreated mice remained tumor- free after B16.
F10 tumor cell implantation (online supplemental figure 
S7A). Hence, IT MVA- TAA-4- 1BBL treatment induced 
strong protective immunological memory against local 
tumor rechallenge.
OVA- specific CD8+ T cells could be readily detected 
prior to rechallenge in mice that had rejected the tumor 
after IT treatment with MVA- OVA-4- 1BBL, but not with 
MVA- OVA (figure 5C). Seven days after tumor cell injec-
tion, the OVA- specific T cell population was significantly 
expanded, indicative of effective tumor recognition 
(figure 5C). Splenocyte OVA257-264 peptide restimulation 
showed that IT MVA- OVA-4- 1BBL therapy induced a large 
population of multicytokine- producing antigen- specific 
CD8+ T cells (figure 5E). Analysis of spleen, blood, TdLN 
and NdLN on day 41 after tumor rechallenge revealed an 
accumulation of OVA- specific CD8+ T cells in all organs 
analyzed (figure 5D). Memory subset examination33 
revealed that OVA- specific TCM cells were equally distrib-
uted over all organs, while TEM cells were mainly found in 
blood, spleen and TdLN but not in the NdLN (figure 5F). 
Next, we analyzed tissue- resident memory T cells (TRM) 
Figure 4 intratumoral MVA- immunotherapy induces rejection of untreated lesions. (A–D) Bilateral tumor model. (A) 
Experimental layout. Balb/c mice received 5×105 and 1×105 CT26.WT tumor cells SC into the right and left flank, respectively. 
Five days later, right flank tumors were immunized IT either with PBS or with the indicated MVA constructs. IT immunization 
was repeated on days 5 and 8 after the first immunization (arrows). (B) Tumor size follow- up (n=10 mice/group) of the treated 
and untreated tumor after PBS IT injection. (C) Tumor size follow- up (n=10 mice/group) of the treated and untreated tumor after 
5×107 TCID50 MVA- Gp70 it injection. (D) Tumor size follow- up (n=10 mice/group) of the treated and untreated tumor after 5×10
7 
TCID50 MVA- Gp70-4- 1BBL it injection. IT, intratumoral; MVA, modified vaccinia Ankara; PBS, phosphate buffered saline; SC, 
subcutaneous.
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that have been shown to play a key role in antitumor 
immunity. Strikingly, we could also detect a significant 
population of resident memory T cells (TRM) exclusively 
located in the TdLN (figure 5F). Likewise, p15E- specific 
CD8+ T cells in the blood were detected pre and post 
rechallenge of mice that cleared primary B16.F10 tumors 
on IT MVA- Gp70-4- 1BBL treatment (online supplemental 
figure S7B). Furthermore, we could identify p15E- specific 
TCM, TEM and TRM cells at day 42 post B16.F10 rechallenge 
(Suppl. Figure S7C- E), whereby the latter were exclu-
sively found in the TdLN (Suppl. Figure S7E). Our results 
demonstrate that IT MVA- TAA-4- 1BBL immunotherapy 
Figure 5 IT MVA- TAA-4- 1BBL treatment protects from local tumor rechallenge and induces epitope spreading. (A) 
Experimental layout. Naïve C57BL/6 mice or long- term survivors (12–36 weeks after tumor clearance) of figure 1A,B were 
rechallenged SC into the tumor- naïve flank of cured mice with 5×105 B16.OVA cells. Peripheral blood was analyzed by flow 
cytometry before (day −6) and after (day 7) after rechallenge. Blood, spleen, NdLN and TdLN mononuclear cells were analyzed 
on day 41 after tumor cell inoculation. (B) Percentage of tumor- free mice over time is displayed (n=5–11 mice/group). Number 
of tumor- free mice per group is shown. (C) Frequency of peripheral blood CD44+ OVA257-264 Dex
+ CD8+ T cells pre- B16 and 
post- B16.OVA rechallenge of naïve mice and long- term survivors after IT MVA- OVA or MVA- OVA-4- 1BBL treatment. (D) 
Frequency of CD44+ OVA257-264 Dex
+ CD8+ T cells in blood, spleen, NdLN and TdLN. (E) Frequency of splenic CD44+ IFNγ+ 
TNFα+ IL2+ CD8+ T cells after restimulation with OVA257-264 peptide. (F) Frequency of CD62L
- CD127+ CD69- OVA257-264 Dex
+ T 
cells (TEM) in blood, spleen, NdLN and TdLN (left). Frequency of CD62L
+ CD127+ OVA257-264 Dex
+ cells (TCM) in blood, spleen, 
NdLN and TdLN (middle). Frequency of CD62L- CD127+ CD69+ OVA257-264 Dex
+ (TRM) in blood, spleen, NdLN and TdLN 41 days 
after B16.OVA cell challenge (right). (G) Experimental layout. Naïve C57BL/6 mice (n=5) or long- term survivors (12–36 weeks 
after tumor clearance, n=18) that rejected B16. OVA tumors on IT MVA- OVA-4- 1BBL were rechallenged SC into the left flank 
with 5×105 B16.F10 cells. (H) Tumor size follow- up. (I) Overall survival. data in A–H expressed as Mean±SEM. (C–F) Two- way 
ANOVA was performed. *P<0.05; **p<0.01; ***p<0.005. (E) one- way ANOVA was performed. *P<0.05; **p<0.01; ***p<0.001. 
Log- rank test on mouse survival was performed for figure 1. ***P<0.001. ANOVA, analysis of variance; IFNγ, interferon-γ; IL2, 
interleukin 2; IT, intratumoral; MVA, modified vaccinia Ankara; NdLN, non- draining lymph node; OVA, ovalbumin; PBL, peripheral 
blood lymphocyte; SC, subcutaneous; SEM, SE of the mean; TdLN, tumor- draining lymph node; TNFα, tumor necrosis factor-α; 
TRM, resident memory T cells.
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led to the induction of a diversified population of tumor- 
specific memory CD8+ T cells encompassing TCM, TEM as 
well as TRM cells.
We next addressed whether MVA- TAA-4- 1BBL IT 
treatment induced the diversification of epitope speci-
ficity from the defined TAA in the vaccination regime, a 
phenomenon known as epitope spreading. To test this, 
we rechallenged mice that rejected B16.OVA tumors 
on IT MVA- OVA-4- 1BBL with B16.F10 cells, which do 
not express OVA (figure 5G). Interestingly, significant 
delay in tumor growth (figure 5H) and mouse survival 
(figure 5I) was observed. These results indicate that IT 
MVA- TAA-4- 1BBL- mediated immune responses do not 
only restrict to the initially TAA encoded in the vaccine 
but also extend to other, tumor- specific antigens.
IT MVA-TAA-4-1BBL cured mice are resistant to systemic 
tumor rechallenge
IT MVA- TAA-4- 1BBL injection induced systemic immune 
responses that mediate control of local recurrent tumors 
and untreated lesions. We reasoned that the tumor- 
specific T cell memory generated by IT MVA injec-
tion might also protect against metastatic recurrences 
(figure 6A). Macroscopic quantification of tumor nodules 
in the lung after intravenous CT26.WT tumor cell injec-
tion showed the development of multiple lesions in naïve 
mice. No macroscopic metastatic lesions were found 
in the lungs of mice that were previously cured with IT 
MVA- Gp70 or MVA- Gp70-4- 1BBL (figure 6B). T cell anal-
ysis revealed an enlarged population of multifunctional 
AH1- specific CD8+ T cells in MVA- Gp70-4- 1BBL cured 
mice (figure 6C).
Taken together, local immunotherapy using MVA genet-
ically modified to express a tumor antigen together with 
the costimulatory molecule 4- 1BBL conveyed strong anti-
tumor activity by combining innate and adaptive immune 
activation. This not only resulted in the induction of 
systemic antitumor effects but also in the generation of 
a potent tumor- specific memory response that protected 
against local and systemic tumor rechallenge.
DISCUSSION
In the present study, we took a novel approach for tumor- 
directed virotherapy and used a non- replicating MVA 
genetically modified to express TAAs and the costim-
ulatory molecule 4- 1BBL. This combines the excellent 
immune- stimulatory properties of MVA and its high safety 
profile with the immune- activating potential of 4- 1BBL. 
IT MVA- TAA-4- 1BBL injection activates a sequence of 
immediate and long- term immune events, ultimately 
resulting in tumor eradication. The induction of multiple 
proinflammatory mediators by IT MVA treatment is 
indicative of a fundamental alteration of the previously 
immune- suppressive TME that facilitates the re- activation 
Figure 6 intratumoral (IT) MVA- TAA-4- 1BBL treated mice are resistant to subsequent systemic tumor rechallenge. (A–C) 
Systemic tumor rechallenge. (A) Experimental layout. Naïve Balb/c mice or long- term survivors of figure 1E,F were rechallenged 
IV with 2×105 CT26.WT cells. Spleen and lungs were analyzed on day 19 after tumor cell injection. (B) Representative 
Photographs of lungs after fixation in Bouin′s solution on day 19 after tumor cell transfer into naïve or cured mice. Total number 
of macroscopic pulmonary metastasis was evaluated (n=3–13 mice/group). (C) Frequency of splenic CD44+ IFNγ+ TNFα+ 
IL2+ CD8+ T cells after restimulation with AH16-14 peptide 19 days after rechallenge. (A–C) n=3–13 mice/group. (B, C) Data are 
expressed as mean±SEM. One- way ANOVA was performed *P<0.05; **p<0.01; ***p<0.001. ANOVA, analysis of variance; IFNγ, 
interferon-γ; IL2, interleukin 2; IV, intravenous; MVA, modified vaccinia Ankara; SEM, SE of the mean; TNFα, tumor necrosis 
factor-α.
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and expansion of tumor- specific T cells. MVA- encoded 
4- 1BBL triggered drastic qualitative and quantitative 
changes in cytotoxic antitumor immune responses that 
were essential for both therapeutic efficacy and formation 
of local and systemic long- term immunologic memory 
against the primary tumor.
We show for the first time that IT injection of active, 
non- replicating MVA conveys potent therapeutic anti-
tumor effects. Interestingly, it has been reported that IT 
delivery of heat- inactivated MVA but not MVA induced 
strong antitumor effects mainly depending on the acti-
vation of cytotoxic T cells.26 In contrast to this study, we 
utilized active MVA encoding for TAA with or without 
additionally expressing 4- 1BBL. Importantly, MVA- TAA 
alone was already effective in delaying tumor growth and 
the adjuvantation with 4- 1BBL significantly improved 
therapeutic efficacy, leading to rejection of established 
tumors within multiple models. Moreover, the antitumor 
effect was independent of the choice of tumor antigen. 
Apart from the model antigen OVA, we investigated the 
endogenous retroviral protein Gp70 for its immunogenic 
potential as TAA. Endogenous retroviral elements are 
epigenetically silenced in healthy tissues but re- activated 
and expressed in various cancers.34 Likewise, Gp70 is 
highly expressed in several murine tumor cell lines.35 In 
humans, there is growing evidence that these transpos-
able elements such as endogenous retroviral sequences 
might have potent immunogenic properties and there-
fore represent excellent TAA targets for cancer immuno-
therapy.36 37 Given the self- nature of Gp70,38 the strong 
therapeutic effects obtained by IT MVA- Gp70-4- 1BBL 
treatment in Gp70- expressing tumor models imply that 
local MVA therapy cannot only induce the rejection of 
tumors expressing neoantigens but also break peripheral 
tolerance to endogenous self- antigens.
IT virotherapy repurposes virus- induced inflammation 
and cell death to alter the immunosuppressive TME.5 
This cascade of events would enhance antitumor- specific 
immunity. Likewise, our data show that MVA infection 
promotes tumor cell death and hence HMGB1 release, 
similar to oncolytic vaccinia virus.39 Moreover, IT injec-
tion of MVA elicited a strong inflammatory response 
within the TME which was accompanied by the induction 
of multiple MVA- related cytokines and chemokines.40 IT 
application of 4- 1BBL- adjuvanted MVA strongly increased 
the concentration of IFNγ and GM- CSF in B16.OVA 
tumors. This infers that the induction of those molecules 
is downstream of 4- 1BB signaling. Indeed, in vitro activa-
tion of OVA- specific CD8+ T cells by MVA- infected tumor 
cells led to the production of large amounts of IFNγ and 
GM- CSF exclusively in the presence of MVA- encoded 
4- 1BBL. Interestingly, a fraction of tumor- infiltrating 
CD8+ T cells in murine and human cancers expresses 
4- 1BB, indicative of previous antigen encounter and 
tumor specificity.20 41 Therefore, it is tempting to specu-
late that the production of both proinflammatory media-
tors within the TME is unleashed by direct interaction of 
pre- existing antigen- specific CD8+ T cells on encounter 
with MVA- OVA-4- 1BBL infected cells. Furthermore, T cell 
activation and subsequent T cell- mediated cytotoxicity in 
tumor tissue could further propagate immunogenic cell 
death in the TME.42
Our data demonstrate a central role for the induction 
of cytotoxic CD8+ T cells on IT MVA- based immuno-
therapy. In contrast to this, systemic antibody depletion 
of CD4+ T cells improved therapeutic efficacy alone or 
in combination with IT MVA- Gp70-4- 1BBL. This is in 
line with published data showing B16.F10 tumor growth 
retardation on anti- CD4 treatment and enhancement of 
agonistic 4- 1BB antibody- mediated therapy.43 The deple-
tion of immunosuppressive CD4+ Treg was implicated in 
the improved antitumor response. Similar effects were 
observed when NK cell depletion and MVA- based immu-
notherapy was combined. Even though NK cells are potent 
mediators of antitumor immunity, they do play a regula-
tory role in antiviral T cell immunity. CD8+ T cells can be 
directly killed by NK cells in vivo,44 thereby suppressing 
the ability of antiviral CD8+ T cells to control infection.45 
We hypothesize that excessive NK cell activation by IT 
MVA- TAA-4- 1BBL injection eliminates pre- existing tumor- 
specific CD8+ T cells infiltrating the tumor. Then, in the 
absence of NK cells, tumor- infiltrating CD8+ T cells would 
get better primed by antigen- presenting cells or directly 
by MVA-4- 1BBL and exert stronger antitumor responses.
Analysis of T cell expansion on IT MVA- TAA-4- 1BBL 
treatment revealed differences in the kinetics of tumor- 
specific (OVA) and virus- specific (MVA) CD8+ T cells. 
While OVA- specific CD8+ T cells peaked as early as day 3 
after injection, we observed the increase of MVA- specific 
CD8+ T cells by day 7. As expected, MVA- directed responses 
were generated de novo from the naïve circulating CD8+ 
T cell pool in the periphery. In contrast, OVA- specific 
CD8+ T cells were expanded by IT MVA injection most 
likely from an antigen- experienced population of tumor- 
specific CD8+ T cells located in or in close vicinity of the 
tumor. The rapid reactivation and expansion of tumor- 
resident T cells after IT immunotherapy was reported 
previously.46 In support of this assumption, we observed 
the downregulation of Lag-3 and PD-1 on tumor- specific 
CD8+ T cells in the tumor after IT administration of MVA- 
TAA-4- 1BBL which implicates the re- acquisition of potent 
effector functions on treatment.
Together, our results support the idea that IT MVA- TAA-
4- 1BBL therapy cannot only generate and recruit de novo 
T cell responses from the periphery but also reinvigorate 
and boost antigen- experienced T cells resident in the 
tumor or local LN. Thus, various tumor categories might 
benefit from our IT administration, irrespective if they 
are already associated with pre- existing T cell responses 
(hot tumors) or lack significant T cell infiltrates (cold 
tumors) thus depending on de novo activation of periph-
eral T cells.47
The expansion of tumor- specific CD8+ T cells was not 
only observed in the tumor but also in the TdLN and even 
preceding their appearance within the tumor. We, there-
fore, investigated MVA- encoded antigen distribution and 
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potential T cell priming in the TdLN and other organs 
upon IT MVA administration. We addressed this by 
performing a comprehensive analysis of the localization 
of MVA within different organs after IT injection. Protein 
expression by MVA and MVA gDNA was mostly confined 
to the tumor site. However, MVA- encoded soluble hFlt3L, 
MVA- encoded luciferase or MVA gDNA were also detected 
in the TdLN, although at significantly lower amounts 
compared with the tumor. Hence, the TdLN could also 
serve as a priming site for tumor- specific T cells. Our 
results are in concordance with previous work showing 
that MVA localizes in the paracortical region of the 
draining LN after footpad injection of MVA.48 In agree-
ment with this, no protein or gDNA was found in the 
NdLN. Interestingly, we could detect low amounts of viral 
DNA in the spleen, blood, lung and liver suggesting some 
leakage of the 4- 1BBL- expressing virus or processed viral 
DNA from the tumor into the blood or lymphatic systems. 
We did not observe signs of liver damage on local MVA- 
TAA-4- 1BBL injection compared with systemic agonistic 
4- 1BB- antibody. Sandin et al reported for agonistic CD40 
antibody to enhance hepatotoxicity when given IV, but 
not IT.49 Hence, our results highlight both the safety and 
specificity of IT MVA- TAA-4- 1BBL injection.
An important aspect of tumor- directed immuno-
therapy is the generation of a systemic antitumor 
immune response that eradicates distant metastases 
and induces long- term tumor immunity. We showed 
that local MVA- TAA-4- 1BBL treatment across different 
tumor models not only elicited immune responses 
within the TME, but also led to systemic antigen- 
specific CD8+ T cell responses in the blood, including 
multifunctional memory populations. In addition, 
our data obtained from the bilateral tumor model 
unambiguously demonstrated that IT MVA injection 
resulted in significant antitumor effects in untreated 
lesions. A clear contribution of 4- 1BBL adjuvanta-
tion on the untreated tumor, however, could not be 
observed in this experimental setup.
Moreover, across many individual experiments and 
different TAAs employed, mice that had rejected mela-
nomas on IT MVA- TAA-4- 1BBL treatment developed 
vitiligo. Vitiligo is a pigmentation disorder with focal 
loss of melanocytes in the skin caused by autoreactive 
CD8+ T cells.50 These cells have been induced by IT 
MVA- TAA-4- 1BBL virotherapy, most likely through 
antigen spread, a phenomenon that describes the 
diversification of epitope specificity from the initial 
focused, dominant epitope- specific immune response, 
for example, Gp70 or OVA. In support of this hypoth-
esis, IT MVA- OVA-4- 1BBL cured mice that were rechal-
lenged with B16.F10 tumor cells lacking the primary 
rejection antigen OVA showed significantly prolonged 
survival compared with naïve mice.
Together, the antitumor response triggered by local 
MVA- TAA-4- 1BBL administration was associated with 
system- wide immunity against the primary tumor. 
Furthermore, our results support the notion that MVA 
IT treatment induces tumor antigen spread which is 
a desirable feature of cancer immunotherapy as it 
broadens the antitumor response and prevents the 
likelihood of tumor escape by TAA loss.
The ability of the immune system to maintain 
memory of previous antigen encounters is the basis 
for long- term immunity. Here, we defined the compo-
nents of immunological memory induced on IT MVA 
administration. Circulating TAA- specific CD8+ T cells 
were detected in mice several months after tumor 
clearance regardless of the tumor model or mouse 
strain used. CD8+ T cell frequencies were significantly 
increased when 4- 1BBL- adjuvanted MVA was used. 
We found that mice that were previously cured with 
IT MVA- TAA-4- 1BBL were more resistant to subcu-
taneous tumor rechallenge with B16.OVA or B16.
F10 than MVA- TAA treated counterparts. Analysis of 
tissues from those mice showed that T cell memory 
subsets were not only found in the circulation but 
also in multiple anatomical sites, suggesting immune 
surveillance. Increased frequencies of antigen- specific 
CD8+ TCM and TEM subsets were detected in spleen and 
blood after local tumor rechallenge of cured mice that 
previously received MVA encoding 4- 1BBL. It is well 
established that 4- 1BBL/4- 1BB signals are particularly 
potent in enhancing the expansion and maintenance 
of CD8+ effector and memory T cells.51 Likewise, MVA- 
encoded 4- 1BBL costimulation enhanced the activa-
tion and effector function of tumor- specific cytotoxic 
T cells which resulted in the formation of a potent 
and diverse memory compartment.
In addition to circulating CD8+ TCM and TEM subsets, 
resident CD8+ TRM cells have been shown to cooperate 
in antitumor immunity.52–54 Interestingly, cured mice 
after IT 4- 1BBL- adjuvanted MVA showed increased 
frequencies of tumor- specific TRM cells exclusively in 
the TdLN after local rechallenge either with B16.OVA 
or B16.F10. Although CD8+ TRM cells were first iden-
tified in the tissues, they can also migrate from the 
tissues and accumulate in the draining LN of mice 
on antigen reencounter.54–56 In line with our results, 
4- 1BB has been shown to promote the establishment 
of an influenza- specific CD8+ TRM pool in the lung 
after intranasal immunization.57 We postulate a rela-
tionship between the expansion of tumor- specific 
CD8+ TRM cells in the TdLN and the better response to 
local secondary tumor rechallenge by cured mice on 
IT 4- 1BBL adjuvanted MVA.
In cancers, memory CD8+ T cells are often dysfunc-
tional due to suboptimal differentiation or mainte-
nance conditions and chronic antigen exposure.58 
This phenomenon is associated with the inability to 
secrete IL-2 and TNFα.59 60 Importantly, IT 4- 1BBL 
adjuvanted MVA generated a highly competent CD8+ 
T cell memory pool, that on reencounter of tumor 
antigen expanded and produced significant amounts 
of IFNγ, TNFα and IL-2 compared with IT MVA in all 
rechallenge models tested.
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In summary, we describe a novel therapeutic plat-
form based on the local injection of a non- replicating 
MVA expressing a TAA in conjunction with 4- 1BBL. 
IT virus injection induced profound proinflamma-
tory changes in the TME leading to reactivation and 
expansion of tumor- specific CD8+ T cells. In addition, 
we demonstrated the generation of a diverse CD8+ T 
cell memory population protecting from local and 
systemic tumor rechallenge. Together with the excel-
lent safety profile of MVA, our preclinical data provide 
a strong rationale for exploring this approach in the 
clinic.
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